WallStreetZenWallStreetZen

NASDAQ: MLYS
Mineralys Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Should I buy or sell MLYS stock?

Based on 1 analyst offering ratings for Mineralys Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MLYS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates MLYS as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -12.86% per year. Learn More

Be the first to know when Wall Street analysts revise their MLYS stock forecasts and price targets.

MLYS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-04-27

1 of 1

Forecast return on equity

Is MLYS forecast to generate an efficient return?

Company
31.92%
Industry
18.55%
Market
169.71%
MLYS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MLYS forecast to generate an efficient return on assets?

Company
26.33%
Industry
23.41%
MLYS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MLYS earnings per share forecast

What is MLYS's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$4.59
Avg 2 year Forecast
-$2.20
Avg 3 year Forecast
-$1.43

MLYS revenue forecast

What is MLYS's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$125.0M
Avg 3 year Forecast
$258.4M

MLYS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MLYS$28.91N/AN/AStrong Buy
NRIX$24.83$34.67+39.62%Strong Buy
NAMS$21.16$51.00+141.02%Buy
IRON$67.30$101.67+51.07%Strong Buy
PGEN$7.00$14.50+107.14%Buy
View Top Biotech Stocks

Mineralys Therapeutics Stock Forecast FAQ

Is Mineralys Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: MLYS) stock is to Strong Buy MLYS stock.

Out of 1 analyst, 1 (100%) are recommending MLYS as a Strong Buy, 0 (0%) are recommending MLYS as a Buy, 0 (0%) are recommending MLYS as a Hold, 0 (0%) are recommending MLYS as a Sell, and 0 (0%) are recommending MLYS as a Strong Sell.

If you're new to stock investing, here's how to buy Mineralys Therapeutics stock.

What is MLYS's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: MLYS) Mineralys Therapeutics's current Earnings Per Share (EPS) is -$4.19. On average, analysts forecast that MLYS's EPS will be -$4.59 for 2026, with the lowest EPS forecast at -$4.54, and the highest EPS forecast at -$4.55. On average, analysts forecast that MLYS's EPS will be -$2.20 for 2027, with the lowest EPS forecast at -$3.70, and the highest EPS forecast at $1.06. In 2028, MLYS's EPS is forecast to hit -$1.43 (min: -$2.33, max: -$0.57).

What is MLYS's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: MLYS) forecast ROE is 31.92%, which is considered strong.

What is MLYS's earnings growth forecast for 2026-2028?

(NASDAQ: MLYS) Mineralys Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.35%.

Mineralys Therapeutics's earnings in 2026 is -$349,576,000.On average, 10 Wall Street analysts forecast MLYS's earnings for 2026 to be -$405,610,788, with the lowest MLYS earnings forecast at -$401,137,400, and the highest MLYS earnings forecast at -$402,684,520. On average, 10 Wall Street analysts forecast MLYS's earnings for 2027 to be -$194,053,113, with the lowest MLYS earnings forecast at -$327,494,465, and the highest MLYS earnings forecast at $93,755,502.

In 2028, MLYS is forecast to generate -$125,988,652 in earnings, with the lowest earnings forecast at -$206,200,219 and the highest earnings forecast at -$50,126,704.

What is MLYS's revenue growth forecast for 2026-2028?

(NASDAQ: MLYS) Mineralys Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.52%.

Mineralys Therapeutics's revenue in 2026 is $0.On average, 10 Wall Street analysts forecast MLYS's revenue for 2026 to be $0, with the lowest MLYS revenue forecast at $0, and the highest MLYS revenue forecast at $0. On average, 10 Wall Street analysts forecast MLYS's revenue for 2027 to be $11,051,744,694, with the lowest MLYS revenue forecast at $2,755,112,164, and the highest MLYS revenue forecast at $37,669,289,630.

In 2028, MLYS is forecast to generate $22,846,991,291 in revenue, with the lowest revenue forecast at $11,522,953,391 and the highest revenue forecast at $31,555,953,532.

What is MLYS's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: MLYS) forecast ROA is 26.33%, which is higher than the forecast US Biotechnology industry average of 23.41%.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.